President’s Message
Top Message
「ASKA VISION 2035」――From Japan, to Asia, and Then to the World.
President, Representative Director
I would like to express my heartfelt gratitude to our stakeholders for their continued support of the Group’s growth.
The business environment surrounding the Group’s core domestic pharmaceutical business is becoming ever more challenging due to such factors as declining birth rates, the graying of society, and annual NHI drug price revisions amid efforts to rein in social security costs. At the same time, there appears to be growing social interest in a wide range of healthcare fields, such as preventive medicine, testing, diagnostics, treatment, and prognosis.
Since the fiscal year ended March 31, 2022 (FY2021), the Group has promoted the Mid-Term Management Plan 2025 with the aim of becoming a total healthcare company with a strong foundation in specialty pharmaceuticals. As a result, we were able to achieve all our numerical targets for the final fiscal year of this plan, with ¥71.1 billion in net sales, operating profit margin of 8.2%, and ROE of 8.0%.
Based on ASKA VISION 2035, we will utilize our domestic pharmaceutical business, which centers on the obstetrics and gynecology field, as a foundation for our rapid expansion into overseas markets, beginning with Asia. Toward this end, we will strengthen our drug discovery research and develop our global businesses.
In addition, we plan to expand the reach of our business fields and create new value by continuing to develop our businesses in animal health, testing and around-the-pill (total healthcare) solutions in order to realize sustainable growth and contribute to society. I would like our Company to utilize the drug discovery capabilities we have cultivated since our founding as the base upon which we will continue to take on challenges and provide value to all our stakeholders.
We appreciate the continued understanding and support of our stakeholders.
Sohta Yamaguchi
President, Representative Director
(As of May 21, 2026)